Advertisement

Pharmaceutical Medicine

, Volume 32, Issue 1, pp 93–93 | Cite as

Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

  • Andrew J. KrentzEmail author
  • Gerardo Rodriguez-Araujo
Publisher Correction

1 Publisher Correction: Pharm Med  https://doi.org/10.1007/s40290-017-0209-3

The original version of this article unfortunately contained a mistake. Table 1 was presented incorrectly. The corrected Table 1 is given below.
Table 1

MACE primary composite endpoints applied in diabetes CVOTs to date

Three-point MACE

Four-point MACE

CV death

CV death

Non-fatal myocardial infarction

Non-fatal myocardial infarction

Non-fatal stroke

Non-fatal stroke

Hospitalization for unstable angina

MACE major adverse cardiovascular events, CV cardiovascular, CVOTs cardiovascular outcome trials

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.ProScientoChula VistaUSA

Personalised recommendations